2008—2022年崇川区疑似预防接种异常反应监测结果  

Surveillance of suspected adverse events following immunization in Chongchuan District from 2008 to 2022

作　　者：顾红 侯晓艳[2] 祁志刚 吴明 GU Hong;HOU Xiaoyan;QI Zhigang;WU Ming(Department of Immunization Planning,Chongchuan District Center for Disease Control and Prevention,Nantong,Jiangsu 226001,China;Nantong Center for Disease Control and Prevention,Nantong,Jiangsu 226001,China)

机构地区：[1]南通市崇川区疾病预防控制中心免疫规划科,江苏南通226001 [2]南通市疾病预防控制中心,江苏南通226001

出　　处：《预防医学》2023年第11期992-996,共5页CHINA PREVENTIVE MEDICINE JOURNAL

基　　金：中国肝炎防治基金会2020年度中国乙肝防控科研基金(YGFK20200038)。

摘　　要：目的了解2008—2022年江苏省南通市崇川区疑似预防接种异常反应(AEFI)发生情况,为疫苗接种安全性评价提供依据。方法通过中国免疫规划信息系统AEFI监测系统收集2008—2022年崇川区AEFI监测资料,包括AEFI病例的人口学信息、预防接种史、实验室检测资料、AEFI发病和临床资料;描述性分析2008—2022年崇川区AEFI发生特征和报告发生率。结果2008—2022年崇川区AEFI报告发生率呈下降趋势(P<0.05),年均报告发生率为50.85/10万剂。免疫规划疫苗AEFI报告发生率为74.67/10万剂,高于非免疫规划疫苗的20.35/10万剂(P<0.05)。报告发生的AEFI以一般反应为主,1937例,报告发生率为44.21/10万剂;异常反应274例,报告发生率为6.25/10万剂;偶合症17例,报告发生率为0.39/10万剂;无疫苗质量事故和接种事故报告。经皮下注射和肌内注射途径的疫苗AEFI报告发生率较高,分别为75.05/10万剂和47.40/10万剂;口服途径的报告发生率较低,为16.41/10万剂。AEFI报告发生率居前五位的疫苗为无细胞百白破b型流感嗜血杆菌(结合)联合疫苗(312.01/10万剂)、7价肺炎球菌多糖结合疫苗(292.14/10万剂)、乙脑灭活疫苗(248.37/10万剂)、ACYW135群脑膜炎球菌多糖疫苗(240.67/10万剂)和麻疹风疹联合减毒活疫苗(229.31/10万剂)。一般反应以发热、红肿和硬结等为主,1878例占96.95%;异常反应以过敏性皮疹为主,241例占87.96%。91.34%的AEFI发生于接种后24 h内。AEFI报告3个月后随访,99.73%的病例痊愈。结论2008—2022年崇川区AEFI报告发生率呈下降趋势。AEFI类型以一般反应为主,预后良好,疫苗接种安全性较高。Objective To investigate the incidence of suspected adverse events following immunization(AEFI)in Chongch-uan District,Nantong City,Jiangsu Province from 2008 to 2022,so as to provide insights into safety assessment of vac-cines.Methods The data on AEFI surveillance in Chongchuan District from 2008 to 2022 were collected through the National Immunization Program Information Management System of China,including demographics,history of vaccination,laboratory tests,incidence of AEFI and clinical characteristics.The epidemiological,clinical characteristics and reported incidence of AEFI were analyzed in Chongchuan District from 2008 to 2022 using a descriptive epidemiological method.Results The reported incidence of AEFI in Chongchuan District from 2008 to 2022 appeared a tendency towards a de-cline(P<0.05),and the annual average reported incidence was 50.85/105.The incidence of AEFI associated with vac-cines included in the national immunization program was significantly higher than that caused by vaccines that were not included in the national immunization program(74.67/105 vs.20.35/105,P<0.05).General reaction was the predominant type of AEFI(1937 cases,44.21/105),and there were 274 cases with abnormal reactions(6.25/105)and 17 cases with coincident syndromes(0.39/105);however,no vaccine quality or vaccination accidents occurred.A high incidence rate was seen in AEFI associated with vaccines administered by subcutaneous(75.05/105)and intramuscular injection(47.40/105),and a low incidence rate was found in AEFI associated with vaccines administered orally(16.41/105).The five highest reported incidence rates of AEFI were found for the combined diphtheria,tetanus,acellular pertussis,poliovirus and Haemophilus influenzae type b vaccine(312.01/105),7-valent pneumococcal polysaccharide-protein conjugate vaccine(292.14/105),inactivated Japanese encephalitis vaccine(248.37/105),Group ACYW135 meningococcal polysaccharide vac-cine(240.67/105)and combined live vaccine for measles and rubella(229.31/105).The general reactions

关 键 词：疑似预防接种异常反应 监测 疫苗 

分 类 号：R186[医药卫生—流行病学]